1 May 2011Americas

For better, for worse? How shifting IP laws change the global life sciences regulatory chessboard

Is your life sciences invention—whether pharmaceutical, biologic, medical device or diagnostic—patentable? Can the term of your patent be extended? If so, what conditions apply and how long can you extend it for? Can proprietary data be used by third parties for product registration, marketing approval and market access? Can your data be used for an upcoming and competing biosimilar?

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Hikma v Amarin: Six takeaways from the pivotal ruling

9 June 2026 A unanimous SCOTUS ruling is being hailed as a major win for Hikma, and for delivering some welcome clarity. Experts tell Marisa Woutersen how its implications could affect pharma patent strategy across the sector.

Americas

Fed Circ rejects Nexus’ appeal in generics row with biopharma firm

8 June 2026 Nexus Pharmaceuticals is knocked back by the US Court of Appeals, which upholds a district court finding that it infringed a rival’s patents.

Americas

Hikma triumphs at SCOTUS in landmark skinny-label ruling

4 June 2026 Justices refuse to place generic drug makers “between a rock and a hard place,” in a landmark ruling clarifying induced patent infringement in pharma.

More features

Hikma v Amarin: Six takeaways from the pivotal ruling

Fed Circ rejects Nexus’ appeal in generics row with biopharma firm

Hikma triumphs at SCOTUS in landmark skinny-label ruling

Pfizer strikes $10.5 billion oncology deal with Chinese biotech

Chadha & Chadha hires former Remfry & Sagar patent partner

Heated LNP litigation puts Moderna and Acuitas in the spotlight

J&J unit's valuable heart pump saved by 'rare' patent defence

Federal Circuit tosses $59m trade secrets judgment against EOFlow

For better, for worse? How shifting IP laws change the global life sciences regulatory chessboard

More on this story

Editor's picks

Editor's picks

More features